Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isoproterenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 0.93 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.93 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.93 |
| ▸ | MAPT | P10636 | 7/20 | 0.93 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.93 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.93 |
| ▸ | TSHR | P16473 | 5/20 | 0.93 |
| ▸ | MEN1 | O00255 | 5/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.93 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.93 |
| ▸ | MTOR | P42345 | 3/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.93 |
| ▸ | LMNA | P02545 | 2/20 | 0.93 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.93 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.93 |
| ▸ | DRD2 | P14416 | 2/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoproterenol SCHEMBL4165 | 0.97 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL3253794 | 0.97 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL29386243 | 0.97 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL29519146 | 0.97 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Levisoprenaline SCHEMBL250806 | 0.97 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Levisoprenaline SCHEMBL29620666 | 0.97 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL4166 | 0.97 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL7627 | 0.95 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Levisoprenaline SCHEMBL4745572 | 0.95 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL3672791 | 0.95 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | disclosed |
| CN-115611750-B | Method for synthesizing isoprenaline hydrochloride | 成都新恒创药业有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-116712425-A | A total phenolic acid conversion product of Saviae Miltiorrhizae radix stem and leaf with antioxidant activity and protecting vascular endothelial cells and myocardial cells, and its application | 南京中医药大学 | 2023-09-08 | — | — | CN | disclosed |
| WO-2023284777-A1 | COPOLYMER FILM, ENZYME CATALYSIS SELF-ASSEMBLY SYNTHESIS METHOD THEREFOR, AND APPLICATION THEREOF | 中国科学院天津工业生物技术研究所 | 2023-01-19 | — | — | WO | disclosed |
| CN-115611750-A | Synthesis method of isoproterenol hydrochloride | 成都新恒创药业有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-115612114-A | Copolymer membrane and enzymatic self-assembly synthesis method and application thereof | 中国科学院天津工业生物技术研究所 | 2023-01-17 | — | — | CN | disclosed |
| CN-115612403-A | Self-assembly strong-adhesion copolymer film, film coating method and application | 中国科学院天津工业生物技术研究所 | 2023-01-17 | — | — | CN | disclosed |
| CN-115612699-A | Copolymer membrane and enzymatic self-assembly synthesis method and application thereof at gas-liquid interface | 中国科学院天津工业生物技术研究所 | 2023-01-17 | — | — | CN | disclosed |
| EP-3459535-B1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2020-08-12 | — | — | EP | disclosed |
| US-20200155491-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2020-05-21 | — | — | US | disclosed |
| CN-104177899-A | Fire retardant for car seat | MA XIAOQUAN | 2014-12-03 | — | — | CN | disclosed |
| CN-104059416-A | Environment-friendly flame retardant for whitewashes | CHUZHOU SI MAITE COMPOSITE MATERIALS CO LTD | 2014-09-24 | — | — | CN | disclosed |
| CN-101883561-B | Novel therapeutic methods for treating CMT and related diseases | PHARNEXT | 2014-07-30 | — | — | CN | disclosed |
| EP-2609916-A1 | New therapeutic approaches for treating CMT and related disorders | Pharnext (FR) | 2013-07-03 | — | — | EP | disclosed |
| US-20130137099-A1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS | KYOTO UNIVERSITY (JP) | 2013-05-30 | — | — | US | disclosed |
| EP-2211846-B1 | New therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2013-02-27 | — | — | EP | disclosed |
| US-20100310641-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2010-12-09 | — | — | US | disclosed |
| CN-101883561-A | Novel therapeutic methods for treating CMT and related diseases | PHARNEXT | 2010-11-10 | — | — | CN | disclosed |
| EP-2211846-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | Pharnext (FR) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009068668-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | SQSTM1, BECN1, CUTA | ADRB2 2163/4885ADRB1 1419/4885ADRB3 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.